3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Pancreatic Neoplasms
7
Colorectal Neoplasms
5
Breast Neoplasms
5
Prostatic Neoplasms
4
COVID-19
4
Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Ovarian Neoplasms
2
Lung Neoplasms
2
Cholangiocarcinoma
2
Untreated Resectable Pancreatic Adenocarcinoma
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Rectal Neoplasms
1
Peripheral Nervous System Diseases
1
Pancreatic Cancer Resectable
1
Neoplasm, Residual
1
Liver Neoplasms
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Klatskin Tumor
1
Hypoxia
1
Hematologic Neoplasms
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Transitional Cell
1
Biliary Tract Neoplasms
1
Interventions
Temozolomide
154
Bevacizumab
88
Radiotherapy
75
Radiation
23
Magnetic Resonance Spectroscopy
23
Lomustine
18
Irinotecan
18
pembrolizumab
17
Surgical Procedures, Operative
16
Carmustine
16
Erlotinib Hydrochloride
12
Nivolumab
11
Specimen Handling
10
Aminolevulinic Acid
10
sargramostim
9
Thalidomide
9
Chemotherapy, Adjuvant
9
Carboplatin
9
Drug Therapy
8
Immunoglobulin G
7
Filgrastim
7
Etoposide
7
Disulfides
7
Cilengitide
7
Sunitinib
6
Sorafenib
6
O(6)-benzylguanine
6
Cyclophosphamide
6
antineoplaston AS 2-1
5
antineoplaston A10
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Glioblastoma
×
Hydroxychloroquine
×
Clear all
NCT01602588
2018-05-03
HCQ
University College, London
Phase 2
Completed
54 enrolled